Avalyn Pharma’s CEO Leads Workshop on Clinical Strategy at IPF Summit
September 18, 2023 12:06 ET
|
Avalyn Pharma Inc.
Seattle, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases,...
Avalyn Pharma Presents Data Showing Favorable Tolerability and Potential of AP01 to Preserve Forced Vital Capacity in Adults with Pulmonary Fibrosis
September 12, 2023 08:00 ET
|
Avalyn Pharma Inc.
Seattle, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, and...
Avalyn Pharma Appoints Business Operations Leader, Melissa Rhodes, to the Role of Chief Operating Officer
September 11, 2023 08:00 ET
|
Avalyn Pharma Inc.
Seattle, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, today...
Avalyn Pharma’s Inhaled Pulmonary Fibrosis Programs to be Highlighted at Upcoming ERS International Congress
September 07, 2023 08:00 ET
|
Avalyn Pharma Inc.
Seattle, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases,...
Avalyn Pharma Expands Executive Team with Appointment of Howard M. Lazarus, MD, FCCP to the Role of Chief Medical Officer
August 07, 2023 08:00 ET
|
Avalyn Pharma Inc.
Seattle, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, today...
Avalyn Pharma Invited to Present at Canaccord Genuity Annual Growth Conference
July 27, 2023 08:00 ET
|
Avalyn Pharma Inc.
SEATTLE , July 27, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases,...
Avalyn Pharma Highlighting Inhalation Platform at Upcoming H.C. Wainwright and Hanson Wade Conferences in June
June 15, 2023 08:00 ET
|
Avalyn Pharma Inc.
SEATTLE, June 15, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases,...
Avalyn Pharma Made Corporate and Clinical Presentations at ATS 2023 Including Results of Long-Term Treatment of Pulmonary Fibrosis with AP01
May 23, 2023 08:00 ET
|
Avalyn Pharma Inc.
SEATTLE, May 23, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing inhaled therapies to treat life-threatening pulmonary diseases, today presented...
Avalyn Pharma Showcasing Therapeutic Approach and Clinical Status at ATS 2023 and the Respiratory Innovation Summit (RIS)
May 11, 2023 08:00 ET
|
Avalyn Pharma Inc.
- Avalyn CEO to Present in Company Showcase and Moderate Panel Discussion at ATS RIS - - Results from Long-Term Treatment of Pulmonary Fibrosis with AP01 to be Presented at ATS - SEATTLE, May 11,...
Avalyn Pharma Presenting at BioEquity Europe
May 10, 2023 07:30 ET
|
Avalyn Pharma Inc.
Seattle, WA, May 10, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing inhaled therapies to treat life-threatening pulmonary diseases, today...